A Multi Site, Placebo Controlled, Double Blind Randomised Clinical Trial Evaluating the Effectiveness of Sodium Zirconium Cyclosilicate Versus Placebo to Enable Safe Optimisation of RASi Therapy in Patients With Diabetic Kidney Disease.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irbesartan (Primary) ; Zirconium silicate (Primary)
Indications Diabetic nephropathies; Hyperkalaemia
Focus Adverse reactions
Acronyms ORTIZ

Most Recent Events

15 Aug 2023 Status changed from not yet recruiting to discontinued due to lack of recruitment.
17 Mar 2022 Planned End Date changed from 15 Aug 2022 to 15 Aug 2023.
17 Mar 2022 Planned primary completion date changed from 15 Feb 2022 to 15 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight